Free Trial

Lifevantage (LFVN) Competitors

Lifevantage logo
$8.93 +0.26 (+2.94%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LFVN vs. DRUG, LXEO, RAPT, AUTL, CGEM, IVA, PRTC, NGNE, ENGN, and FDMT

Should you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Inventiva (IVA), PureTech Health (PRTC), Neurogene (NGNE), enGene (ENGN), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

Lifevantage vs. Its Competitors

Lifevantage (NASDAQ:LFVN) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Lifevantage has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.17, indicating that its stock price is 717% less volatile than the S&P 500.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lifevantage has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$228.53M0.50$9.81M$0.7412.06
Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-67.04

In the previous week, Lifevantage had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.29 beat Lifevantage's score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Lifevantage Positive
Bright Minds Biosciences Positive

Lifevantage has a net margin of 4.29% compared to Bright Minds Biosciences' net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Bright Minds Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage4.29% 33.75% 15.26%
Bright Minds Biosciences N/A -20.96%-20.66%

Lifevantage currently has a consensus target price of $30.50, suggesting a potential upside of 241.74%. Bright Minds Biosciences has a consensus target price of $81.00, suggesting a potential upside of 29.92%. Given Lifevantage's higher probable upside, research analysts plainly believe Lifevantage is more favorable than Bright Minds Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Bright Minds Biosciences
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Summary

Lifevantage beats Bright Minds Biosciences on 10 of the 16 factors compared between the two stocks.

Get Lifevantage News Delivered to You Automatically

Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LFVN vs. The Competition

MetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ Exchange
Market Cap$113.26M$18.25B$6.17B$10.68B
Dividend Yield2.09%1.65%5.72%4.86%
P/E Ratio12.0618.4229.6628.53
Price / Sales0.502.37580.15129.26
Price / Cash7.8513.1737.1261.42
Price / Book3.253.1512.086.53
Net Income$9.81M$472.95M$3.32B$276.85M
7 Day Performance-0.50%5.24%-0.29%0.15%
1 Month Performance-15.56%-1.97%5.75%1.68%
1 Year Performance-28.71%-6.97%65.71%32.74%

Lifevantage Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LFVN
Lifevantage
4.3426 of 5 stars
$8.93
+2.9%
$30.50
+241.7%
-30.2%$113.26M$228.53M12.06260
DRUG
Bright Minds Biosciences
3.098 of 5 stars
$64.97
+2.7%
$81.00
+24.7%
+31.8%$445.81MN/A-69.86N/APositive News
LXEO
Lexeo Therapeutics
3.0536 of 5 stars
$8.20
-0.5%
$17.00
+107.3%
-8.3%$444.97M$650K-2.5258Analyst Forecast
Analyst Revision
RAPT
Rapt Therapeutics
3.7261 of 5 stars
$26.35
-1.6%
$24.78
-6.0%
+109.5%$443.05M$1.53M-1.8680Trending News
Analyst Upgrade
Analyst Revision
AUTL
Autolus Therapeutics
3.7728 of 5 stars
$1.65
-0.6%
$9.12
+452.7%
-65.1%$441.80M$10.12M-1.96330Analyst Forecast
CGEM
Cullinan Therapeutics
3.6207 of 5 stars
$7.83
+5.8%
$26.00
+232.1%
-49.1%$437.15MN/A-2.4230Positive News
Insider Trade
Gap Up
IVA
Inventiva
3.758 of 5 stars
$4.61
+1.3%
$16.14
+250.2%
+96.0%$435.26M$9.95M0.00100
PRTC
PureTech Health
0.2672 of 5 stars
$18.00
0.0%
N/A-18.0%$435.03M$4.83M0.00100News Coverage
Short Interest ↑
NGNE
Neurogene
1.7982 of 5 stars
$31.62
+4.7%
$46.17
+46.0%
-38.5%$431.15M$930K-7.3490
ENGN
enGene
2.9935 of 5 stars
$8.29
-1.2%
$19.50
+135.2%
-10.5%$429.50MN/A-4.3631
FDMT
4D Molecular Therapeutics
3.4673 of 5 stars
$9.67
+8.7%
$30.40
+214.4%
+27.4%$415.65M$40K-2.74120Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NASDAQ:LFVN) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners